MétaCan
Menu
← Back to cohort

S1769 Effects of Risankizumab on the Extraintestinal Manifestations of Crohn's Disease

2025· article· en· W4417195803 on OpenAlexaboutno aff
Hannah O'Neill, Oscar Noble, Poojasree Pasupuleti, Bincy Abraham, Christopher Fan

Bibliographic record

VenueThe American Journal of Gastroenterology · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsnot available
Fundersnot available
KeywordsDiseaseCrohn's diseaseSeverity of illnessInflammatory bowel diseaseSingle CenterStatistical significanceSubgroup analysis

Abstract

fetched live from OpenAlex

Introduction: Crohn’s disease (CD), characterized by chronic transmural inflammation of the GI tract, can lead to strictures & fistulas, obstruction, & cancer. Additionally, a wide range of debilitating extra-intestinal manifestations (EIMs) can occur. EIM response to CD treatment is variable & does not always coincide with IBD response. Biologic options for CD treatment now include risankizumab (RZB), an interleukin-23 inhibitor (IL-23i). This analysis aimed to assess RZB effects on EIMs & determine any baseline characteristics that predict response. Methods: This retrospective, single center study included CD patients receiving RZB from 2022 to 2024. Baseline characteristics were examined to determine predictors of EIM response. Variables included demographics, markers of disease location/severity (Montreal Classification, fecal calprotectin, inflammatory markers), & prior medical therapies. Clinical parameters included Harvey-Bradshaw Index & Simple Endoscopic Score for CD. Exclusion criteria included loss of follow-up & dual biologic therapy. Statistical analyses were performed using Python. Results: Of 202 CD patients who received RZB, 121 met criteria for analysis. Median diagnosis age was 27, 64% were women, and 79% White. Disease location varied; 46% had ileocolonic disease & remainder were evenly split (isolated ileal or colonic.) Most patients had prior biologic exposure. Thirty-9 (32%) patients had baseline arthralgia with minimal additional EIMs (<3%). In those with baseline arthralgia, median diagnosis age was higher (31 years vs 23.5, P = 0.009), & patients were seen more (17 times vs 12, P = 0.009). Of those with baseline arthralgia, 54% had improvement with RZB. This subgroup had less historic TNF-α exposure & lower baseline ESR (9 vs 19.5, P = 0.041). Thirteen patients without arthralgia developed symptoms on RZB & were older at diagnosis. Baseline patient demographics and markers of disease location/severity were similar between all groups. Conclusion: This retrospective study of CD patients on RZB found minimal baseline indicators of EIM response. Patients with baseline arthralgia were older at diagnosis, & of this subset, those with arthralgia improvement were less likely to have historic TNF-α therapy. Those who developed arthralgia after drug initiation were older at diagnosis. Demographics, disease classification, baseline disease severity, and inflammatory markers except ESR were not effective at predicting arthralgia response to RZB.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.004
GPT teacher head0.236
Teacher spread0.232 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicInflammatory Bowel Disease→French-language works237,207→